

Premas Life Sciences signs agreement with IncellDx

29 January 2018 | News

The commercial partnership brings the power of cell by cell multiplex diagnostics for solid tumours carcinomas that can now be analyzed for molecular and protein biomarkers by flow cytometry.



New Delhi based Premas Life Sciences has signed a distribution agreement with a molecular diagnostics company, IncellDx. The commercial partnership brings the power of cell by cell multiplex diagnostics for solid tumours carcinomas that can now be analyzed for molecular and protein biomarkers by flow cytometry.

IncellDx's OncoTect assays offer single cell proteomic and genomics marker based diagnostics and a prognostic solution for early detection and staging for cancer patients with more targeted immuno-onco therapies.

The distribution agreement includes IncellDx's patented single-cell assays for quantifying PD-L1 on tumour cells and immune cell subtypes; patented single-cell assay for HPV E6/E7 mRNA detection in cervical samples; and, and its inCellPREP single-cell preparation kit for solid tissues including tumours.

A successful study has been completed by the researchers at AIIMS, New Delhi, utilizing IncellDx's next generation (3Dx) investigational molecular assay which quantifies E6, E7 mRNA overexpression in single cells simultaneously with the measurement of cell cycle and cell proliferation, the hallmark of progressive disease.